Ab­bott plots new paths to clin­i­cal tri­al di­ver­si­ty, join­ing bio­phar­ma push for broad­er in­clu­sion

Clin­i­cal tri­als have a di­ver­si­ty prob­lem. That’s the open­ing state­ment on Ab­bott’s new web­site to pro­mote its lat­est di­ver­si­ty ef­forts — and the rea­son why it’s lay­ing out con­crete steps for change.

While lack of di­ver­si­ty isn’t ex­act­ly shock­ing news in bio­phar­ma, the Covid-19 pan­dem­ic and resurg­ing racial in­equities over the past two years have pushed the is­sue to the fore­front with ad­vo­cates now hope­ful for re­al change.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER